The theoretical basis of fragment-based drug discovery (FBDD) is to screen out active fragment molecules and extend new drug molecules to obtain highly active drug candidates. Unlike screening millions of compound libraries that directly search for drug-size (drug-size, that is, molecules with the same size as the drug molecule), the essence of FBDD is not to screen analogs of known compounds but cultivate and design drugs. The latest trend in drug discovery has shifted to target leads with lower molecular weight and higher hydrophilicity. BOC Sciences has established Low MW Fragment Library and these compounds with low MW can cover a wider chemical space and are easier for structural optimization, showing a great potential for becoming medicine.
Figure 1. Fragment library and screening against DC-SIGN. (Pearce, N.; et al. 2016)
At BOC Sciences, our Low MW Fragment Library contains more than 4,000 fragments, which is a reliable source of high-quality fragments. We cooperate with leading experts in the field of FBDD to design and supply top-level fragment libraries, aiming to meet different requirement of each client.
Table1. The summary of the BOC Sciences Low MW Fragment Library characteristics
Parameter | Value |
MW | 100-225 |
ClogP | -3-3 |
Number of Rotatable Bonds | ≤3 |
Number of H Donors | ≤3 |
Number of H Acceptors | ≤3 |
TPSA | 0-100 Å2 |
Compounds with‘undesirable’functionalities | Removed |
Number of Ring | 1-3 |
BOC Sciences provides professional, rapid and high-quality services of Low MW Fragment Library design at competitive prices for global customers. Personalized and customized services of Low MW Fragment Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
BOC Sciences has rich experience in working with global customers in custom library synthesis of compounds and generating small to medium-sized libraries of target compounds. Our knowledge in generating a large number of target molecules in a remarkably shorter time enables quick biological screenings for affinities. With the target properties in mind, we deliver target molecules, by applying our extensive knowledge in drug discovery.